ClinicalTrials.gg
RecruitingNCT01094327Updated Nov 20, 2026

Proteinuria in Pre and Post Transplant

An observational study in Proteinuria, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Miami · Observational

How we know

From the registry’s dates

  • Started Feb 2008; still recruiting 18 years 9 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
100
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Proteinuria with a site in United States — 20 open to participants now, 25 under way, 9 of them phase 3. Proteinuria · United States.

Planned enrollment
15th of 29
100 · median 100
Started
2008
with 2 others
Observational
29 of 126
4 open now
Primary completion
2027-11
later than 9 of 23 live
Registered
38th of 126
by date

Among the 126 studies in Proteinuria with a site in United States, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 3 that started in 2008, is one of 29 observational ones, reaches primary completion later than 9 of the 23 other live ones, and was the 38th registered.

Proteinuria

330 studies on the registry are indexed under Proteinuria; 45 are open to participants now.

Browse Proteinuria studies →

Open to participants now

20 of the 126 studies in Proteinuria with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Proteinuria studies recruiting now, 13 (39%) set no upper age limit and 16 (48%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Proteinuria with a site in United States, or all of them as a file.
02

Study summary

Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.

Read the detailed description

This study will retrospectively review patient's medical records for protein in the urine, blood creatinine and kidney biopsy results. Also character of the fluid used to flush the kidney before transplant will be analyzed.

03

Conditions studied

  • Proteinuria

Keywords

  • focal segmental glomerulosclerosis
04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric population up to the age of 25 years old, with biopsy diagnosed of FSGS (focal segmental glomerulosclerosis).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kidney transplant recipients
  • Pediatric males and females up to the age of 25 years old.

Exclusion criteria

Exclusion Criteria:

  • Transplant recipients other than kidney
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
100 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Explain mechanisms behind the development of proteinuria in patients immediately after receiving a kidney transplant

    chart review

    Time frame: through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
  • University of Miami Miller School of Medicine Transplant Clinic
    Miami, Florida 33136, United States
    Recruiting
    • George Burke, M.D. · Contactgburke@med.miami.edu · 305-355-5111
    • George Burke, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2008 (actual). Primary completion is estimated for Nov 2027, 237 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2010
First posted
Mar 26, 2010
StartActual
Feb 2008
Primary completionEst.
Nov 30, 2027was Nov 2026
CompletionEst.
Nov 30, 2027was Nov 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Nov 30, 2027
Nov 20, 2026
Study completion
Nov 30, 2026→Nov 30, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Nov 30, 2026→Nov 30, 2027
    Study completion Nov 30, 2026→Nov 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01094327
Responsible party
George W. Burke (Professor of Surgery, University of Miami) — Principal investigator
First posted
Mar 26, 2010
Start date
Feb 2008
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

George Burke, M.D.
Contact
gburke@med.miami.edu
305-355-5111
Lissett Moni
Contact
ltueros@med.miami.edu
305-243-5235
George Burke, M.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion